Lyric Bio

Executive Summary

Lyric Bio is addressing the critical global shortage of immunoglobulin therapies, particularly IVIg, which are traditionally derived from human plasma donations. The company's proprietary tissue engineering platform creates high-density, tissue-mimicking bioreactors that produce human donor-sourced immunoglobulins in vitro, dramatically reducing dependence on plasma collection. This biomanufacturing innovation aims to provide a scalable, consistent, and cost-effective supply of these life-saving medicines for patients with immune deficiencies and autoimmune disorders. By leveraging cutting-edge tissue engineering and bioreactor design, Lyric Bio's platform has the potential to revolutionize the plasma-derived therapy market, which faces recurring shortages due to limited donor availability and complex manufacturing processes. The company's initial focus on IVIg positions it in a multi-billion-dollar market with strong demand tailwinds. If successful, Lyric could fundamentally transform the production of plasma-derived biologics, offering a reliable alternative to donor-dependent supply chains and expanding patient access globally.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Round80% success
• Q1 2027Strategic Partnership with Pharma Company60% success
• TBDPreclinical Proof-of-Concept Data Release50% success